PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Intellia Therapeutics, Inc. (NTLA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS45826J1051
CUSIP45826J105
SectorHealthcare
IndustryBiotechnology
IPO DateMay 6, 2016

Highlights

Market Cap$1.70B
EPS (TTM)-$5.45
PEG Ratio-0.10
Total Revenue (TTM)$43.09M
Gross Profit (TTM)$35.51M
EBITDA (TTM)-$521.07M
Year Range$13.95 - $34.87
Target Price$59.12
Short %18.07%
Short Ratio6.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: NTLA vs. CRSP, NTLA vs. AAPL, NTLA vs. FVRR, NTLA vs. SCHD, NTLA vs. BEAM, NTLA vs. GOOGL, NTLA vs. VGT, NTLA vs. PRME, NTLA vs. BMY, NTLA vs. SE

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Intellia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%JuneJulyAugustSeptemberOctoberNovember
-36.50%
12.73%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Intellia Therapeutics, Inc. had a return of -45.39% year-to-date (YTD) and -30.07% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-45.39%25.45%
1 month-10.39%2.91%
6 months-35.29%14.05%
1 year-30.07%35.64%
5 years (annualized)4.25%14.13%
10 years (annualized)N/A11.39%

Monthly Returns

The table below presents the monthly returns of NTLA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-21.88%34.84%-14.35%-22.21%-0.09%4.68%17.11%-14.38%-8.42%-30.80%-45.39%
202321.64%-5.35%-7.22%1.29%-1.30%9.45%3.80%-11.46%-15.64%-20.78%18.28%2.90%-12.61%
2022-20.02%4.53%-26.48%-32.53%-5.89%12.18%25.12%-7.26%-6.83%-5.68%-2.50%-32.20%-70.49%
202115.11%-3.45%32.74%-4.34%-2.38%116.05%-12.39%13.17%-16.43%-0.87%-13.51%2.81%117.35%
2020-18.81%12.09%-8.39%10.14%29.99%20.05%-15.27%21.17%-7.88%20.42%64.04%38.53%270.82%
20193.59%7.71%12.15%-9.95%-9.75%17.94%10.57%-21.60%-5.92%-6.48%38.81%-15.35%7.47%
201833.71%1.56%-19.20%-5.07%35.36%0.96%-2.70%16.19%-7.47%-40.67%5.48%-23.79%-28.98%
2017-1.45%10.53%-1.33%3.41%-21.35%39.62%5.25%24.88%18.16%25.23%-27.63%-14.65%46.61%
201633.80%-27.80%-11.38%2.80%-12.49%-19.04%14.30%-16.76%-40.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NTLA is 18, indicating that it is in the bottom 18% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of NTLA is 1818
Combined Rank
The Sharpe Ratio Rank of NTLA is 1717Sharpe Ratio Rank
The Sortino Ratio Rank of NTLA is 1818Sortino Ratio Rank
The Omega Ratio Rank of NTLA is 1919Omega Ratio Rank
The Calmar Ratio Rank of NTLA is 2222Calmar Ratio Rank
The Martin Ratio Rank of NTLA is 1515Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


NTLA
Sharpe ratio
The chart of Sharpe ratio for NTLA, currently valued at -0.50, compared to the broader market-4.00-2.000.002.004.00-0.50
Sortino ratio
The chart of Sortino ratio for NTLA, currently valued at -0.40, compared to the broader market-4.00-2.000.002.004.006.00-0.40
Omega ratio
The chart of Omega ratio for NTLA, currently valued at 0.95, compared to the broader market0.501.001.502.000.95
Calmar ratio
The chart of Calmar ratio for NTLA, currently valued at -0.34, compared to the broader market0.002.004.006.00-0.34
Martin ratio
The chart of Martin ratio for NTLA, currently valued at -1.13, compared to the broader market0.0010.0020.0030.00-1.13
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.90, compared to the broader market-4.00-2.000.002.004.002.90
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.87, compared to the broader market-4.00-2.000.002.004.006.003.87
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.54, compared to the broader market0.501.001.502.001.54
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 4.19, compared to the broader market0.002.004.006.004.19
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 18.72, compared to the broader market0.0010.0020.0030.0018.72

Sharpe Ratio

The current Intellia Therapeutics, Inc. Sharpe ratio is -0.50. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Intellia Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.50
2.90
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Intellia Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-90.58%
-0.29%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Intellia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Intellia Therapeutics, Inc. was 91.96%, occurring on Oct 31, 2024. The portfolio has not yet recovered.

The current Intellia Therapeutics, Inc. drawdown is 90.58%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.96%Sep 7, 2021794Oct 31, 2024
-72.99%Mar 12, 2018507Mar 16, 2020178Nov 25, 2020685
-61.52%Jun 1, 2016251May 30, 201788Oct 3, 2017339
-44.32%Jan 20, 202133Mar 8, 202134Apr 26, 202167
-44.12%Nov 1, 201731Dec 14, 201756Mar 8, 201887

Volatility

Volatility Chart

The current Intellia Therapeutics, Inc. volatility is 28.86%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%JuneJulyAugustSeptemberOctoberNovember
28.86%
3.86%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Intellia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Intellia Therapeutics, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items